Enzalutamide Improves Survival for Castration- Resistant Prostate Cancer in Phase III Clinical Trial

August 24, 2012 by  
Filed under Prostate Cancer News

A Phase III clinical trial on prostate cancer has revealed that the lives of men diagnosed with Castration- Resistant prostate cancer were significantly improved with Enzalutamide.

This is one of the few recently discovered drugs that readily are useful in treating cancer of the prostate that have resisted hormonal therapy. The findings of this study were published in The New England Journal of Medicine.

Enzalutamide was administered to these patients who already failed to be treated of chemotherapy. The following are more details you need to know the study:

Enzalutamide treatment significantly improves survival in men with castration-resistant prostate cancer, demonstrate phase III trial results published in The New England Journal of Medicine.

Men randomly assigned to receive the androgen receptor-signaling inhibitor after chemotherapy had a median overall survival of 18.4 months compared with just 13.6 months for placebo-treated patients.

Multivariate analysis showed that this survival benefit occurred in patients after adjustment for baseline characteristics, regardless of whether they were stratified by age and Eastern Cooperative Oncology Group (ECOG) status, geographic location, disease extent by imaging, and biochemical factors including prostate-specific antigen, report Howard Scher (Memorial Sloan-Kettering Cancer Center, New York, USA) and co-authors.

“These results validate androgen-receptor signaling as a key therapeutic target throughout the clinical spectrum of prostate cancer, including in men who have received previous chemotherapy,” they say.

The study, which included 1199 men treated with enzalutamide 160 mg/day (n=800) or placebo (n=399), was halted after planned interim analysis after 520 deaths showed a hazard ratio for overall survival of 0.63. The patient groups had received a median of 8.3 and 3.0 months’ treatment, respectively.

Enzalutamide was also shown to be significantly better than placebo for all secondary endpoints: reduction of PSA level by 50% or more (54 vs 2%); soft tissue response (29 vs 4%); quality of life response rate (43 vs 18%); time to PSA progression (8.3 vs 3.0 months); radiographic progression-free survival (8.3 vs 2.9 months); and time to first skeletal event (16.7 vs 13.3 months).

Patients given the androgen receptor-signaling inhibitor had higher rates of all grades of fatigue, diarrhea, musculoskeletal pain, headache, and hot flashes than controls. Five (0.6%) patients given enzalutamide experienced seizures, although predisposing factors were noted in most of these men.

Commenting on the findings, Alan Ashworth, chief executive of The Institute of Cancer Research, one of two sites where the trial was conducted, said in a press statement: “What we’re seeing now is an unprecedented period of success for prostate cancer research, with four new drugs shown to extend life in major clinical trials in just two years, and several others showing promise.

“It truly is a golden age for prostate cancer drug discovery and development.” Source.

This is really good news seeing that this medication extends the lives of those who have been diagnosed with the advanced prostate cancer. Many lives can now be extended with this treatment, especially those of men diagnosed with castration- resistant prostate cancer.

This is good for patients living with this condition and hopefully more research like this will help to find a permanent cure to cancer of the prostate.

Castration-resistant cancer is fast killer for men suffering from this condition, and this treatment should really be a welcomed development for men affected by this late stage of this disease.

Below Are Other Related Articles Among 1,000+ Prostate Cancer Articles On
This HUGE 4+ Year Old Prostate Cancer Victory Authority Website:

(95% of these 1,000+ Prostate Cancer Articles on this website
are written by our Expert In -house Writers, after lots of research.
The remaining 5% are news articles and videos from relevant sources!)

  1. US Oncologists to Prescribe Enzalutamide for Metastatic Castration-resistant Prostate cancer (mCRPC)
  2. Management of Castration-Resistant Prostate Cancer
  3. Enzalutamide (MDV3100) – a New Drug from Medivation, can Increase Lifespan for Men with Terminal Prostate Cancer
  4. Cabozantinib Shows More Efficacy in Treating Metastatic Castration-Resistant Prostate Cancer (CRPC)
  5. MicroRNA 125b, a Molecule and new Target for Castration Resistant Prostate Cancer Identified
  6. Survival Stage Iv Prostate Cancer
  7. Factors That Can Influence Prostate Cancer Survival Rate
  8. New Study Recommends Continuous Prostate Cancer Therapy to Improve Survival Rates of Patients
  9. Zytiga Shows Efficacy in Blocking Advanced Prostate Cancer and Improving Survival Rates of Patients
  10. Prostate Cancer Survival Rates
  11. Prostate Cancer Final Stages – Symptoms, Diagnosis and Treatment of stages III and IV
  12. Advanced Prostate Cancer 2b Survival – How You Can!
  13. Married Men Have Better Survival Rate for Prostate Cancer
  14. Prostate Cancer 2b Survival
  15. Robotic Prostate Surgery Yields Better Survival Rates Than Radiation Treatment – A World-Renowned Prostate Cancer Expert Reports

Speak Your Mind

Tell us what you're thinking... !